We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MBOT Stock Gains Following FDA Submission of the LIBERTY System
Read MoreHide Full Article
Microbot Medical Inc. (MBOT - Free Report) recently announced that it has submitted a 510(k) premarket notification to the FDA for its LIBERTY system. The 510(k) submission follows the successful completion of its multi-center, single-arm trial to evaluate the performance and safety of LIBERTY in human subjects undergoing Peripheral Vascular Interventions.
The company anticipates FDA marketing clearance during the second quarter of 2025, with U.S. commercialization activities expected to commence after the clearance.
Likely Trend of MBOT Stock Following the News
Following the announcement, shares of the company moved 2% north and closed at $1.02 on Wednesday. In the year-to-date period, MBOT shares have lost 37.8% against the industry’s 6.5% growth. The S&P 500 increased 27.3% in the same time frame.
Meanwhile, MBOT currently has a market capitalization of $16.9 million.
Image Source: Zacks Investment Research
More on MBOT’s LIBERTY System & Its Recent Developments
The LIBERTYEndovascular Robotic Surgical System by Microbot Medical is an innovative robotic solution for endovascular procedures. It is notable for being the first single-use robotic system to address significant barriers in vascular interventions. Unlike traditional robotic systems that require large capital investment and infrastructure, LIBERTY is designed for efficiency, mobility, and ease of use. The system aims to increase procedural efficiency and expand access to robotic-assisted surgeries. In October, MBOT completed a pivotal clinical trial (ACCESS-PVI) evaluating LIBERTY’s safety and effectiveness in peripheral vascular interventions.
The successful completion of the ACCESS-PVI trial marked a significant milestone for Microbot Medical, demonstrating the effectiveness of the LIBERTY system in clinical settings. This accomplishment not only strengthened the company’s position in the healthcare market but also supported the 510(k) submission to the FDA, which has now set the stage for future commercialization efforts. The encouraging results from the trial, along with positive feedback from physicians, signify strong prospects for Microbot Medical and its innovative robotic surgical technologies.
In August, Microbot Medical entered a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures using its LIBERTY Endovascular Robotic System. Following positive results from Phase 1, which demonstrated LIBERTY's technical capabilities and potential applications, the new phase will focus on developing the system's ability to perform simulated cardiovascular interventional procedures across two Corewell Health sites located five miles apart.
The same month, Microbot Medical agreed with Emory University to explore the potential for collaboration on autonomous robotics in endovascular procedures. Under this agreement, Emory University will investigate the feasibility of integrating the LIBERTY Endovascular Robotic Surgical System with an imaging system to create an autonomous robotic system for these procedures.
Favorable Industry for MBOT
Per a report in Grand View Research, the global peripheral vascular devices market size is estimated to be worth $10.4 billion in 2024 and is anticipated to reach $14.8 billion by 2030 at a CAGR of 5.9%.
The robust growth is likely to be driven by the increasing incidence of cardiac diseases, the rising global geriatric population base triggering incidence rates of target diseases, novel product launches and an increase in collaboration and mergers by key players.
MASI’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 17.10%. Masimo’s shares have risen 37.2% year to date compared with the industry’s 6.7% growth.
AngioDynamics, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 38.2% for 2025. ANGO’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 31.71%.
AngioDynamics’ shares have lost 8.9% year to date against the industry’s 6.7% growth.
Globus Medical, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.7%. GMED’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.1%. Its shares have risen 56.5% year to date compared with the industry’s 6.7% growth.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
MBOT Stock Gains Following FDA Submission of the LIBERTY System
Microbot Medical Inc. (MBOT - Free Report) recently announced that it has submitted a 510(k) premarket notification to the FDA for its LIBERTY system. The 510(k) submission follows the successful completion of its multi-center, single-arm trial to evaluate the performance and safety of LIBERTY in human subjects undergoing Peripheral Vascular Interventions.
The company anticipates FDA marketing clearance during the second quarter of 2025, with U.S. commercialization activities expected to commence after the clearance.
Likely Trend of MBOT Stock Following the News
Following the announcement, shares of the company moved 2% north and closed at $1.02 on Wednesday. In the year-to-date period, MBOT shares have lost 37.8% against the industry’s 6.5% growth. The S&P 500 increased 27.3% in the same time frame.
Meanwhile, MBOT currently has a market capitalization of $16.9 million.
Image Source: Zacks Investment Research
More on MBOT’s LIBERTY System & Its Recent Developments
The LIBERTYEndovascular Robotic Surgical System by Microbot Medical is an innovative robotic solution for endovascular procedures. It is notable for being the first single-use robotic system to address significant barriers in vascular interventions. Unlike traditional robotic systems that require large capital investment and infrastructure, LIBERTY is designed for efficiency, mobility, and ease of use. The system aims to increase procedural efficiency and expand access to robotic-assisted surgeries. In October, MBOT completed a pivotal clinical trial (ACCESS-PVI) evaluating LIBERTY’s safety and effectiveness in peripheral vascular interventions.
The successful completion of the ACCESS-PVI trial marked a significant milestone for Microbot Medical, demonstrating the effectiveness of the LIBERTY system in clinical settings. This accomplishment not only strengthened the company’s position in the healthcare market but also supported the 510(k) submission to the FDA, which has now set the stage for future commercialization efforts. The encouraging results from the trial, along with positive feedback from physicians, signify strong prospects for Microbot Medical and its innovative robotic surgical technologies.
In August, Microbot Medical entered a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures using its LIBERTY Endovascular Robotic System. Following positive results from Phase 1, which demonstrated LIBERTY's technical capabilities and potential applications, the new phase will focus on developing the system's ability to perform simulated cardiovascular interventional procedures across two Corewell Health sites located five miles apart.
The same month, Microbot Medical agreed with Emory University to explore the potential for collaboration on autonomous robotics in endovascular procedures. Under this agreement, Emory University will investigate the feasibility of integrating the LIBERTY Endovascular Robotic Surgical System with an imaging system to create an autonomous robotic system for these procedures.
Favorable Industry for MBOT
Per a report in Grand View Research, the global peripheral vascular devices market size is estimated to be worth $10.4 billion in 2024 and is anticipated to reach $14.8 billion by 2030 at a CAGR of 5.9%.
The robust growth is likely to be driven by the increasing incidence of cardiac diseases, the rising global geriatric population base triggering incidence rates of target diseases, novel product launches and an increase in collaboration and mergers by key players.
MBOT’s Zacks Rank & Stocks to Consider
MBOT carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks from the medical industry are Masimo (MASI - Free Report) , AngioDynamics (ANGO - Free Report) and Globus Medical (GMED - Free Report) .
Masimo, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated growth rate of 10.4% for 2025. You can see the complete list of today’s Zacks #1 Rank stocks here.
MASI’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 17.10%. Masimo’s shares have risen 37.2% year to date compared with the industry’s 6.7% growth.
AngioDynamics, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 38.2% for 2025. ANGO’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 31.71%.
AngioDynamics’ shares have lost 8.9% year to date against the industry’s 6.7% growth.
Globus Medical, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.7%. GMED’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.1%. Its shares have risen 56.5% year to date compared with the industry’s 6.7% growth.